Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Alexander disease (AxD) is a rare neurodegenerative disorder of the astrocytes comprised of two clinical forms: AxD Type I and Type II manifesting with various degrees of macrocephaly, spasticity, ataxia and seizures and leading to psychomotor regression and death.
Features include always present findings: Dysmetria, Ataxia, Babinski sign, and Dysarthria and others; and very common findings: Macrocephaly, Intellectual disability, Agenesis of corpus callosum, and Overactive reflexes (hyperreflexia) and others. 74 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 26 | Seizure, Ataxia, Diffuse demyelination of the cerebral white matter |
GFAP encodes glial fibrillary acidic protein (432 aa). GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells Highest expression in Brain Spinal cord cervical c-1 (9,334 TPM) and Brain Substantia nigra (3,372 TPM).
Alexander disease is caused by mutations in the GFAP gene on chromosome 17.
The GFAP protein participates in GFAP gene expression is inhibited by ERBB4:TAB2:NCOR1, EEF1A1 dissociates from p-GFAP, and p-GFAP:GFAP dissociates from LAMP2a multimer pathways.
GFAP is classified as a druggable target with score 2.5.
Suggestive Findings Alexander disease should be suspected in individuals with the following age-related clinical and brain MRI findings. Clinical Findings Neonates • Weak suck, feeding difficulties, hypotonia, and myoclonus • Progressive psychomotor impairment or developmental regression • Megalencephaly with frontal bossing Note: Though the terms megalencephaly and macrocephaly are sometimes used interchangeably, macrocephaly refers to head circumference that is more than two standard deviations above the mean adjusting for age and sex, whereas megalencephaly refers to increased volume of brain parenchyma. Macrocephaly – which reflects the size of intracranial contents as well as bone and scalp – may result from megalencephaly but also other medical issues, such as hydrocephalus or thickening of the skull. • Seizures • Occasional hydrocephalus secondary to aqueductal stenosis • CSF protein elevation Children • Developmental delay (slow attainment of developmental milestones or failure to achieve later milestones) • Seizures • Megalencephaly • Gradual loss of intellectual function • Regression after mild head injury or seizure • Dysarthria (in those children who attain speech) • Failure to thrive Juveniles • Developmental delay • Seizures • Bulbar/pseudobulbar signs with nasal speech, dysphagia, dysphonia • Failure to thrive • Intractable vomiting • Scoliosis • Autonomic dysfunction Adults • Bulbar/pseudobulbar signs • Pyramidal tract signs • Cerebellar signs • Dysautonomia • Sleep disturbance • Gait disturbance • Hemiparesis/hemiplegia or quadriparesis/quadriplegia • Diplopia or oculomotor abnormalities Brain MRI Findings Based on a multi-institutional retrospective survey of MRI studies of 217 individuals with leukoencephalopathy , it has been suggested that the presence of four of the five following criteria establishes an MRI-based diagnosis of Alexander disease, which can lead to targeted genetic testing: • Extensive cerebral white matter abnormalities with a frontal preponderance • Periventricular rim of decreased signal intensity on T2-weighted images and elevated signal intensity on T1-weighted images • Abnormalities of the basal ganglia and thalami that may include one or both of the following: • Swelling and increased signal intensity on T2-weighted images • Atrophy and increased/decreased signal intensity on T2-weighted images • Brain stem abnormalities, particularly involving the medulla and midbrain • Contrast enhancement of one or more of the following: ventricular lining, periventricular rim, frontal white matter, optic chiasm, fornix, basal ganglia, thalamus, dentate nucleus, and brain stem Table 1. Alexander Disease: MRI Features by Age of Presentation
No approved treatments are currently available for Alexander disease. The disease remains an area of unmet medical need.
No clinical practice guidelines for Alexander disease have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with Alexander disease, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 8. Recommended Evaluations Following Initial Diagnosis in Individuals with Alexander Disease
Table 10. Recommended Surveillance for Individuals with Alexander Disease
System/Concern |
|---|
3 clinical trials registered, 2 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE3. Research is sponsored by a mix of industry and academic institutions.
96 publications have been identified in PubMed for Alexander disease. Research spans Basic Science / Preclinical (32%), Case Report / Case Series (23%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 31 |
Data assembled from 9 of 12 sources · Last updated Oct 4, 2026, 6:16 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Head and neck |
5 |
Progressive macrocephaly, Macrocephaly, Large face |
Eyes | 5 | Pendular nystagmus, Abnormal eye movements (abnormality of eye movement), Ptosis |
Bones and joints | 4 | Sideways curvature of the spine (scoliosis), Excessive outward curvature of the upper spine (kyphosis), Mild bone density loss (osteopenia) |
Digestive system | 3 | Nausea and vomiting, Difficulty swallowing (dysphagia), Constipation |
Hormones | 3 | Diabetes mellitus, Hypothyroidism, Precocious puberty |
Skin | 2 | Excessive sweating (hyperhidrosis), Hyperpigmented nevi |
Lungs and breathing | 2 | Sleep apnea, Difficulty breathing (respiratory insufficiency) |
Heart and blood vessels | 2 | Hypertension, Sudden cardiac death |
Muscles | 2 | Low muscle tone (hypotonia), Muscle weakness |
Lab test results | 1 | Increased CSF protein concentration |
Growth and development | 1 | Failure to thrive |
Alexander disease is a progressive disorder affecting cerebral white matter. It is most readily recognized in infants and children. Adults can also be affected, but manifestations and diagnosis may be under-recognized. Life expectancy is variable. Many individuals with Alexander disease present with nonspecific neurologic manifestations. Previous classification recognized four forms: neonatal (sometimes considered a subset of the infantile form), infantile, juvenile, and adult. Based on a prior review of reports of GFAP variants, the infantile form of Alexander disease accounts for 42% (124/293) of reported individuals with an identifiable GFAP pathogenic variant; the juvenile form accounts for 22% (63/293); and the adult form accounts for 33% (96/293) (see Table 3 [pdf]). Ten (3%) of the 293 individuals with an identifiable GFAP pathogenic variant were reported to be asymptomatic [, , , , ]. The current clinical status of these individuals is unknown. Additional case series have suggested a two-group classification system (Type I and Type II) or a three-group classification system (cerebral, bulbospinal, intermediate) . See for a comparison of select features seen in the different forms (based on age of onset). Table 4. Alexander Disease: Comparison of Forms by Select Features
Neonatal | Infantile | Juvenile | Adult |
|---|---|---|---|
Typical age at presentation | 1st mo of life | Infancy or childhood | Childhood or adolescence |
Core neurologic manifestations | Lack of developmental progression; motor impairment w/o spasticity; seizures; megalencephaly; hydrocephalus | Developmental delay or developmental regression; seizures; megalencephaly | Bulbar/pseudobulbar signs w/nasal speech, dysphagia, dysphonia; failure to thrive; intractable vomiting; scoliosis; autonomic dysfunction |
Other findings | Feeding difficulties (failure to thrive) | Failure to thrive | Short stature |
Source: GeneReviews — "Alexander Disease"
A number of genotype-phenotype correlations have been observed for some recurrent variants, albeit with a limited number of affected individuals (see Table 3 [pdf] for references and ). It is possible that given the variable expressivity of the disorder, exceptions may occur.
Source: GeneReviews — "Alexander Disease"
Penetrance appears to be nearly 100% in individuals with the infantile and juvenile forms . Reports of molecularly confirmed familial cases support the existence of asymptomatic adults with Alexander disease [, , , ].
Source: GeneReviews — "Alexander Disease"
Neonatal | Infantile | Juvenile | Adult |
|---|---|---|---|
Periventricular rim | + | + | + or - |
Basal ganglia or thalamus involvement | +++ | ++ | + or - |
Brain stem involvement | Symmetric signal abnormality of medulla | Mass-like brain stem lesions | Medullary cervical cord atrophy |
Contrast enhancing structures | Frequent in basal ganglia | Variable | Frequently present in posterior fossa structures |
Source: GeneReviews — "Alexander Disease"
Alexander disease is usually considered in the differential diagnosis of infants who present with megalencephaly, developmental delay, spasticity, and seizures, or in older individuals who have a preponderance of brain stem signs and spasticity with or without megalencephaly or seizures. Differential Diagnosis in Neonates, Infants, and Juveniles Table 6. Genes of Interest in the Differential Diagnosis of the Neonatal, Infantile, and Juvenile Forms of Alexander Disease
Gene(s) | Disorder | Features of Differential Diagnosis Disorder |
|---|---|---|
ABCD1 | X-linked adrenoleukodystrophy (X-ALD) | Male children present w/regression in motor cognitive skills. |
ARSA | Arylsulfatase A deficiency (metachromatic leukodystrophy, MLD)1 | Developmental regression in early childhood |
ASPA | Canavan disease1 | Hypotonia, head lag, macrocephaly, difficulties w/suck swallow; DD ± regression; MRI: involvement of subcortical WM globus pallidus thalami |
GALC | Krabbe disease1 | Early feeding difficulties, hypotonia, irritability; Developmental regression seizures; MRI: involvement of thalami cerebellar WM; MRI: involvement of deep WM primarily w/sparing of subcortical WM until later in disease course; thickening/enhancement of optic nerves peripheral nerves |
GCDH | Glutaric acidemia type 11 | Macrocephaly, DD, extrapyramidal signs (often preceded by an acute encephalopathy during infancy); MRI: involvement of basal ganglia |
MLC1 | Megalencephalic leukoencephalopathy w/subcortical cysts 1 2A1 | Megalencephaly during infancy, DD, seizures; MRI: involvement of subcortical WM |
L2HGDH | L-2-hydroxyglutaric aciduria (OMIM 236792)1 | DD, seizures, dysarthria, ataxia (often w/insidious progression); MRI: involvement of subcortical, WM basal ganglia; anterior to posterior involvement of WM |
MRI: sparing of brain stem cerebellum; no enhancement PEX1PEX6PEX12(13 assoc genes)2 | Zellweger spectrum disorder (ZSD) | Neonatal-infantile onset: hypotonia, feeding difficult... |
Source: GeneReviews — "Alexander Disease"
Genetic testing for GFAP is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Alexander disease has been reported in the published literature.
System/Specialist | Evaluation | Comment |
|---|---|---|
Neurologic | Complete neurologic assessment incl history, physical exam, eval of head circumference | Review clinical MRI findings w/affected individual caregivers.; Perform formal, age-appropriate developmental assessment (in children).; Discuss symptomatic therapy.; Determine if EEG is needed. Primary care |
physician | History physical exam | To facilitate care coordination after receiving info about diagnosis mgmt plan Genetic |
counseling | Discussion led by genetics professionals1 | To inform patients their families re nature, MOI, implications of Alexander disease to facilitate medical personal decision making Family support/ |
resources | Discussion w/patient, family, caregivers | To assess family social structure to determine availability of adequate support system, need for social work involvement parental or caregiver support, need for home nursing referral, use of community or such as Parent to Parent Speech/language pathologist or |
feeding specialist | Swallow eval | Some programs may offer a clinical eval while others may recommend a study, such as videofluoroscopic swallowing study (also called modified barium swallow) or fiberoptic endoscopic eval. Speech/language |
pathologist | Speech/language eval | To identify impairments in receptive expressive language determine if speech/language therapy /or AAC would help improve communication skills |
Physical therapist | Physical eval | To evaluate range of motion, strength, coordination, tone; develop a plan for improving gross motor function (e.g., ambulation, mobility) Occupational |
therapist | Physical eval | To evaluate fine motor activities (incl dexterity handwriting) develop plan to improve self-care skills (e.g., dressing, toileting, grooming) Physiatrist |
(rehab doctor) | History physical exam | To evaluate function guide team in maximizing abilities Orthopedic |
specialist | History physical exam | To evaluate scoliosis hip dislocation (may be done in conjunction w/physiatry) |
Gastroenterologist | History physical exam | To assess feeding/eating, digestive problems (incl constipation gastroesophageal reflux), nutrition using history, growth measurements, (if needed) gastrointestinal investigations |
Nutritionist | Review caloric intake expended energy | To determine nutritional fluid needs to ensure adequate growth Pulmonologist (or sleep medicine |
physician) | Lung breathing eval | To determine whether respiratory compromise is present (from weakness, scoliosis, or aspiration) assess for sleep apnea (often central in etiology) |
Urologist | Review bladder function | To determine if upper or lower motor neuron involvement of bladder requires intervention |
Psychologist | Discussion of medical diagnosis | Psychological assessment for older patients to determine awareness understanding of disease its consequences |
Neuropsychologist | Formal eval (when age appropriate) to incl standardized metrics of cognition other areas of brain development | To determine impact of disrupted cerebral pathways on learning cognitive development, as well as develop plan to optimize learning strategies AAC = augmentative alternative communication; MOI = mode of inheritance 1. |
Treatment of Manifestations in Individuals with Alexander Disease Manifestation/Concern | Treatment | Considerations DD/ID |
Source: GeneReviews — "Alexander Disease"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Alexander Disease"
3 trials found
Evaluation
Frequency |
|---|
parameters | Height, weight, head circumference, heart rate, vital signs | Every 6 mos |
Neurology | Neurologic exam | Every 3-6 mos (Younger persons those early in disease course may require more frequent assessment.) |
Development | Monitor developmental progress educational needs. | At each visit |
PT/OT | Gross fine motor rating scales | Per therapist |
Swallow eval | Clinical or radiologic eval | Annually1 Speech/ |
Language | Expressive receptive language skills | Per therapist |
Gastrointestinal | History eval of GI tract for esophageal dysfunction, reflux, vomiting, constipation | Annually1 Orthopedics |
Source: GeneReviews — "Alexander Disease"
Phenotype severity distribution: 11 always present features, 15 very common features, 21 common features.
Estimated prevalence: Unknown (Unknown prevalence).
Patient case studies | 22 | 23% |
Disease patterns and progression | 15 | 16% |
Research summaries | 12 | 13% |
Testing and diagnosis research | 8 | 8% |
New treatment approaches | 5 | 5% |
Other research | 2 | 2% |
Clinical study results | 1 | 1% |
Osumi KM (2026). [PMID: 42239084](https://pubmed.ncbi.nlm.nih.gov/42239084/). *bioRxiv*. [Basic Science / Preclinical]
Pesco MT (2026). [PMID: 41837797](https://pubmed.ncbi.nlm.nih.gov/41837797/). *Journal of child neurology*. [Basic Science / Preclinical]
Schwarz S (2026). [PMID: 41443241](https://pubmed.ncbi.nlm.nih.gov/41443241/). *Neuropediatrics*. [Epidemiology / Natural History]
Sevagamoorthy A (2026). [PMID: 42176404](https://pubmed.ncbi.nlm.nih.gov/42176404/). *Mol Genet Metab*. [Epidemiology / Natural History]
Bachetti T (2026). [PMID: 41349291](https://pubmed.ncbi.nlm.nih.gov/41349291/). *Molecular genetics and metabolism*. [Basic Science / Preclinical]
Hagemann TL (2026). [PMID: 41024483](https://pubmed.ncbi.nlm.nih.gov/41024483/). *Annals of clinical and translational neurology*. [Case Report / Case Series]
Waldman AT (2026). [PMID: 41513585](https://pubmed.ncbi.nlm.nih.gov/41513585/). *Annals of clinical and translational neurology*. [Case Report / Case Series]
Goya-Iglesias N (2026). [PMID: 42150925](https://pubmed.ncbi.nlm.nih.gov/42150925/). *Redox Biol*. [Other]
Zhang J (2026). [PMID: 41581419](https://pubmed.ncbi.nlm.nih.gov/41581419/). *Pediatric neurology*. [Gene Therapy / Novel Therapeutics]
Lin NH (2026). [PMID: 42196383](https://pubmed.ncbi.nlm.nih.gov/42196383/). *Int J Mol Sci*. [Basic Science / Preclinical]
AI-curated news mentioning Alexander disease
Updated Sep 9, 2026
Ionis Pharmaceuticals secures the first targeted approval for Alexander disease, marking a significant milestone in rare disease treatment. Meanwhile, Novo Nordisk and Novartis face setbacks with late-stage trial cancellations and Phase 3 failures in cardiovascular and muscular dystrophy indications.
Between September 19th and September 30th, the FDA is due to rule on 8 rare disease therapies. Sanfilippo syndrome, Alexander disease, ataxia-telangiectasia, and MCT8 deficiency have never had an approved treatment. That could change within 3 weeks. By Jason Hunter, independent writer at Trial ... Between September 19th and September 30th, the FDA is due to rule on 8 rare disease therapies. Sanfilippo syndrome, Alexander disease, ataxia-telangiectasia, and MCT8 deficiency have never had an approved treatment. That could change within 3 weeks. By Jason Hunter, independent writer at Trial Friend After approval, companies finalize manufacturing release, insurers make coverage decisions, and gene therapies are administered only at qualified treatment centers that must be activated. Patient support programs typically open within days of approval and are the fastest first step for families. Drug companies disclose PDUFA dates in press releases and investor filings when the FDA accepts their applications. Aggregated calendars, including Trial Friend's rare disease FDA calendar, compile those disclosures and cite each company announcement as the source. 8 rare disease FDA decisions arrive by Sept 30th, 2026. Sanfilippo, Alexander disease, A-T, and MCT8 deficiency could all see their first approved treatment. Approval gave Alexander disease its first disease-modifying therapy. Emcitate for MCT8 deficiency (September 28th). Egetis Therapeutics' tiratricol treats a rare genetic disorder in which thyroid hormone cannot enter the cells that need it, causing severe developmental impairment in boys. No approved treatment exists.
New research explores cellular models for studying Alexander disease through the functional analysis of primary rat astrocytes. This study contributes to understanding the disease mechanisms and potential therapeutic targets.
FDA approves Zanvastro for Alexander disease, marking a significant milestone as the first approved treatment for this rare neurological condition. This approval highlights the ongoing advancements in rare disease therapies.
The U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients.